Anfield Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Anfield Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.43K	Buy	+100	New	+$7.25K	﹤0.01%	472

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Anfield Capital Management's BBIO Position: Q1 2026 in Review

Anfield Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 100 shares worth $7.43K. The stake represents ﹤0.01% of the portfolio and ranks #472 among its holdings.

460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Anfield Capital Management held 100 shares of BridgeBio Pharma worth $7.43K as of Q1 2026.
BridgeBio Pharma was a new Anfield Capital Management position in Q1 2026.
BridgeBio Pharma made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #472 holding.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.